Newborn

Margot’s story: A CDKL5 diagnosis through genome-based newborn screening

Two brave parents said yes to genome-based newborn screening—and found answers quickly when their newborn began having seizures.

Blog
Patient Stories

Key Takeaways

  • Genome-based newborn screening can identify rare genetic conditions before traditional testing pathways reach a diagnosis.
  • Early genetic results helped Margot’s family quickly understand the cause of her seizures.
  • A confirmed diagnosis allowed the family to pursue targeted treatment and connect with other families facing the same condition.
  • Early answers can reduce the long diagnostic journey many rare disease families experience.

A Small Decision Shortly After Birth

After Lili and Colin’s baby was born at a New York hospital, they were invited to participate in a research program called the GUARDIAN study, which offers genome testing for newborns.

Their daughter received a simple cheek swab shortly after birth.

“We said yes,” Lili recalls. “The expectation was that we’d enroll and never think about it again, because we expected nothing to be wrong.”

Six weeks later, their newborn—Margot—began having seizures.

Around the same time, results from the GUARDIAN study arrived.

Those results revealed that Margot had a rare genetic condition—CDKL5 deficiency disorder—providing an explanation for the seizures and helping guide treatment decisions.

For many families affected by rare disease, receiving a diagnosis can take four to five years on average, and sometimes even longer. In Margot’s case, answers came within weeks of the first symptoms.

Early Genetic Results Informed Treatment

The genome sequencing results provided a clear diagnosis.

“I’ll never forget getting the GeneDx report,” Lili says. “It was very informative and emotionally overwhelming. But the information gave us power.”

Armed with a diagnosis, Margot’s family was able to take immediate action.

They found a pediatric neurologist in New York City who specializes in CDKL5 deficiency disorder. The physician prescribed a specific medication to control Margot’s seizures, and Margot gained access to experimental therapies and supportive care options.

For the family, having a diagnosis early meant they could focus on the right care from the start.

Finding Strength in Community

After receiving Margot’s diagnosis, Lili began searching for other families who understood what they were going through.

At first, the family believed they were the only ones in New York City raising a child with CDKL5 deficiency disorder.

Through Facebook, Lili eventually connected with two other families whose children share the same diagnosis—and who were about to move to the city.

Today, the families meet regularly and support each other.

“The ability to share news, tips, and advice is invaluable,” Lili explains. “It’s a very different type of support than what you get from well-meaning friends and family, because these families truly understand the experience.”

Enjoying Every Moment

Margot is now one-and-a-half years old.

According to her mother, she’s thriving in her own unique way.

“Everyone talks about what a great baby Margot is, because she really is,” Lili says. “She’s curious, smart, and chatty. A little stubborn—she knows what she likes and doesn’t like. And she absolutely loves to snuggle.”

She also loves being outdoors and exploring the world around her.

Reflecting on her journey, Lili says the advice she received from other parents has helped her focus on what matters most.

“Another parent reminded me that my job right now is to enjoy Margot—because she’s a sweet little baby,” Lili says. “Not to miss this phase of her life because I’m focused so much on her treatment.”

A genetic diagnosis gives families a path forward
Diagnosis Drives Action
Real patients. Real stories
About the authors
Jess Hess
,
MSc, GC, CPC
Associate Director of Patient Advocacy & Engagement

Jess Hess, MSc, GC, CPC, is Associate Director of Patient Advocacy & Engagement at GeneDx. With expertise in genetic counseling and patient advocacy, Jess works to help patients and families navigate the genetic testing journey and access the information, resources, and support they need to make informed healthcare decisions.

View profile
Leanne Owens MPH GeneDx
Leanne Owens
,
MPH
Manager, Patient Advocacy & Engagement, GeneDx

Leanne Owens, MPH, is Manager of Patient Advocacy & Engagement at GeneDx. Through patient-centered education and advocacy, Leanne helps individuals and families understand and navigate the genetic testing process, connecting them with the resources and support needed to make informed healthcare decisions.

View profile

Related articles

Newborn
Genome sequencing for newborn screening: First results from the GUARDIAN Study

Early results from the GUARDIAN study show how genomic newborn screening can identify serious genetic conditions before symptoms appear, expanding the future of newborn screening and early diagnosis.

NICU
Earlier genetic answers are changing the NICU journey

Every NICU clinician has encountered an infant whose condition does not fully align with the expected diagnosis. This article explores key insights from a recent NANNcast conversation with Dr. Linda Genen, Chief Medical Officer at GeneDx and practicing neonatologist, and examines how rapid genome sequencing is helping care teams identify underlying genetic conditions earlier, reduce diagnostic uncertainty, and support more informed care decisions.

Rare Disease Diagnostics
Genomics
Genetic Testing
Exome
Genome
Diagnosis Drives Action: A collaboration built on answers, clarity, and hope

Diagnosis Drives Action is a GeneDx initiative elevating the voices of patients, families, clinicians, and advocacy organizations to show how a genetic diagnosis can create a path forward—from informed care and community connection to research opportunities and hope.

Science that serves people

We’re scientists, but we’re also parents, siblings, and caregivers who understand how powerful an answer can be.